Buscar
Congreso SOLACI

Artículos del autor

Dr. Omar Tupayachi

Member of the Editorial Board of solaci.org
Chronic Ischemic cardiopathy

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been...
Dr. Omar Tupayachi -
Antiplatelet

AHA 2025 | DAPT-MVD: Extended DAPT vs. Aspirin Monotherapy After PCI in Multivessel Disease

In patients with multivessel coronary artery disease who remain stable 12 months after drug-eluting stent (DES) stenting,...
Dr. Omar Tupayachi -
Antiplatelet

AHA 2025 | TUXEDO-2: Post-PCI Antiplatelet Management in Diabetic Patients with Multivessel Disease — Ticagrelor or Prasugrel?

Choosing the optimal P2Y12 inhibitor for diabetic patients with multivessel coronary artery disease undergoing percutaneous coronary intervention...
Dr. Omar Tupayachi -
Coronary disease

AHA 2025 | DECAF: Coffee Consumption vs. Abstinence in Patients with Atrial Fibrillation: Recurrence or Myth?

The link between coffee consumption and arrhythmia has been met with contradicting recommendations. It is widely believed...
Dr. Omar Tupayachi -
Calcified Lesions

CALIPSO: Calcified Lesions and Use of OCT

Percutaneous coronary intervention (PCI) in calcified lesions remains one of the most challenging scenarios in daily practice,...
Dr. Omar Tupayachi -
Coronary disease

Retrospective Analysis of DCB vs DES in Side-Branch Treatment

Coronary bifurcations are one of the most challenging scenarios in percutaneous coronary intervention (PCI) due to their...
Dr. Omar Tupayachi -
Infrapatellar

TCT 2025 | LIFE-BTK: Three-Year Results of the Everolimus-Eluting Resorbable Scaffold in Infrapopliteal Lesions in Patients with Critical Limb Ischemia

Patients with chronic limb-threatening ischemia (CLTI) are among the most challenging in endovascular revascularization. While endovascular treatment...
Dr. Omar Tupayachi -
Antiplatelet

TCT 2025 | ANDES Trial: Short-Term DOAC vs. DAPT After Percutaneous Left Atrial Appendage Occlusion

Percutaneous left atrial appendage occlusion (LAAO) is an established alternative to chronic anticoagulation in patients with non-valvular...
Dr. Omar Tupayachi -

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Dr. Omar Tupayachi - 0
Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Dr. Omar Tupayachi - 0
Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Dr. Juan Manuel Pérez - 0
Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

Noticias Institucionales

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad